183 related articles for article (PubMed ID: 35984750)
21. Iron deposition in Parkinson's disease by quantitative susceptibility mapping.
Chen Q; Chen Y; Zhang Y; Wang F; Yu H; Zhang C; Jiang Z; Luo W
BMC Neurosci; 2019 May; 20(1):23. PubMed ID: 31117957
[TBL] [Abstract][Full Text] [Related]
22. Measuring the iron content of dopaminergic neurons in substantia nigra with MRI relaxometry.
Brammerloh M; Morawski M; Friedrich I; Reinert T; Lange C; Pelicon P; Vavpetič P; Jankuhn S; Jäger C; Alkemade A; Balesar R; Pine K; Gavriilidis F; Trampel R; Reimer E; Arendt T; Weiskopf N; Kirilina E
Neuroimage; 2021 Oct; 239():118255. PubMed ID: 34119638
[TBL] [Abstract][Full Text] [Related]
23. Inflammation and age-related iron accumulation in F344 rats.
Hunter RL; Liu M; Choi DY; Cass WA; Bing G
Curr Aging Sci; 2008 Jul; 1(2):112-21. PubMed ID: 20021380
[TBL] [Abstract][Full Text] [Related]
24. Interactions of dopamine, iron, and alpha-synuclein linked to dopaminergic neuron vulnerability in Parkinson's disease and Neurodegeneration with Brain Iron Accumulation disorders.
Wise RM; Wagener A; Fietzek UM; Klopstock T; Mosharov EV; Zucca FA; Sulzer D; Zecca L; Burbulla LF
Neurobiol Dis; 2022 Dec; 175():105920. PubMed ID: 36351559
[TBL] [Abstract][Full Text] [Related]
25. Iron, the substantia nigra and related neurological disorders.
Snyder AM; Connor JR
Biochim Biophys Acta; 2009 Jul; 1790(7):606-14. PubMed ID: 18778755
[TBL] [Abstract][Full Text] [Related]
26. Cell specific quantitative iron mapping on brain slices by immuno-µPIXE in healthy elderly and Parkinson's disease.
Friedrich I; Reimann K; Jankuhn S; Kirilina E; Stieler J; Sonntag M; Meijer J; Weiskopf N; Reinert T; Arendt T; Morawski M
Acta Neuropathol Commun; 2021 Mar; 9(1):47. PubMed ID: 33752749
[TBL] [Abstract][Full Text] [Related]
27. Up-regulation of microRNA-375 ameliorates the damage of dopaminergic neurons, reduces oxidative stress and inflammation in Parkinson's disease by inhibiting SP1.
Cai LJ; Tu L; Li T; Yang XL; Ren YP; Gu R; Zhang Q; Yao H; Qu X; Wang Q; Tian JY
Aging (Albany NY); 2020 Jan; 12(1):672-689. PubMed ID: 31927536
[TBL] [Abstract][Full Text] [Related]
28. Iron transport in Parkinson's disease.
Hirsch EC
Parkinsonism Relat Disord; 2009 Dec; 15 Suppl 3():S209-11. PubMed ID: 20082992
[TBL] [Abstract][Full Text] [Related]
29. The whole-brain pattern of magnetic susceptibility perturbations in Parkinson's disease.
Acosta-Cabronero J; Cardenas-Blanco A; Betts MJ; Butryn M; Valdes-Herrera JP; Galazky I; Nestor PJ
Brain; 2017 Jan; 140(1):118-131. PubMed ID: 27836833
[TBL] [Abstract][Full Text] [Related]
30. Low Levels of Prohibitin in Substantia Nigra Makes Dopaminergic Neurons Vulnerable in Parkinson's Disease.
Dutta D; Ali N; Banerjee E; Singh R; Naskar A; Paidi RK; Mohanakumar KP
Mol Neurobiol; 2018 Jan; 55(1):804-821. PubMed ID: 28062948
[TBL] [Abstract][Full Text] [Related]
31. Nifedipine prevents iron accumulation and reverses iron-overload-induced dopamine neuron degeneration in the substantia nigra of rats.
Ma Z; Zhou Y; Xie J
Neurotox Res; 2012 Nov; 22(4):274-9. PubMed ID: 22259026
[TBL] [Abstract][Full Text] [Related]
32. Repulsive Guidance Molecule a (RGMa) Induces Neuropathological and Behavioral Changes That Closely Resemble Parkinson's Disease.
Korecka JA; Moloney EB; Eggers R; Hobo B; Scheffer S; Ras-Verloop N; Pasterkamp RJ; Swaab DF; Smit AB; van Kesteren RE; Bossers K; Verhaagen J
J Neurosci; 2017 Sep; 37(39):9361-9379. PubMed ID: 28842419
[TBL] [Abstract][Full Text] [Related]
33. Quinoprotein adducts accumulate in the substantia nigra of aged rats and correlate with dopamine-induced toxicity in SH-SY5Y cells.
Wang N; Wang Y; Yu G; Yuan C; Ma J
Neurochem Res; 2011 Nov; 36(11):2169-75. PubMed ID: 21785836
[TBL] [Abstract][Full Text] [Related]
34. Gene Co-expression Analysis of the Human Substantia Nigra Identifies ZNHIT1 as an SNCA Co-expressed Gene that Protects Against α-Synuclein-Induced Impairments in Neurite Growth and Mitochondrial Dysfunction in SH-SY5Y Cells.
McCarthy E; Barron A; Morales-Prieto N; Mazzocchi M; McCarthy CM; Collins LM; Sullivan AM; O'Keeffe GW
Mol Neurobiol; 2022 May; 59(5):2745-2757. PubMed ID: 35175558
[TBL] [Abstract][Full Text] [Related]
35. Gene co-expression analysis of the human substantia nigra identifies BMP2 as a neurotrophic factor that can promote neurite growth in cells overexpressing wild-type or A53T α-synuclein.
Goulding SR; Sullivan AM; O'Keeffe GW; Collins LM
Parkinsonism Relat Disord; 2019 Jul; 64():194-201. PubMed ID: 31000327
[TBL] [Abstract][Full Text] [Related]
36. Intrapallidal lipopolysaccharide injection increases iron and ferritin levels in glia of the rat substantia nigra and induces locomotor deficits.
Zhang J; Stanton DM; Nguyen XV; Liu M; Zhang Z; Gash D; Bing G
Neuroscience; 2005; 135(3):829-38. PubMed ID: 16165292
[TBL] [Abstract][Full Text] [Related]
37. Iron and aluminum increase in the substantia nigra of patients with Parkinson's disease: an X-ray microanalysis.
Hirsch EC; Brandel JP; Galle P; Javoy-Agid F; Agid Y
J Neurochem; 1991 Feb; 56(2):446-51. PubMed ID: 1988548
[TBL] [Abstract][Full Text] [Related]
38. Parkinson's disease iron deposition caused by nitric oxide-induced loss of β-amyloid precursor protein.
Ayton S; Lei P; Hare DJ; Duce JA; George JL; Adlard PA; McLean C; Rogers JT; Cherny RA; Finkelstein DI; Bush AI
J Neurosci; 2015 Feb; 35(8):3591-7. PubMed ID: 25716857
[TBL] [Abstract][Full Text] [Related]
39. Progressive iron accumulation induces a biphasic change in the glutathione content of neuroblastoma cells.
Núñez MT; Gallardo V; Muñoz P; Tapia V; Esparza A; Salazar J; Speisky H
Free Radic Biol Med; 2004 Oct; 37(7):953-60. PubMed ID: 15336311
[TBL] [Abstract][Full Text] [Related]
40. In vivo protein targets for increased quinoprotein adduct formation in aged substantia nigra.
Yu G; Liu H; Zhou W; Zhu X; Yu C; Wang N; Zhang Y; Ma J; Zhao Y; Xu Y; Liao L; Ji H; Yuan C; Ma J
Exp Neurol; 2015 Sep; 271():13-24. PubMed ID: 25956828
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
